FDA Warning Letter Roundup: Issue 3 - When Marketing Claims Outrun What You Actually Validated

Last issue we looked at Asanuma Corporation's Warning Letter and the FDA's position that being a contract manufacturer does not transfer or reduce your compliance obligations. This issue, the pattern shows up again, but from a different angle entirely.

This time it's not one facility relying on a supplier's certificate of analysis. It's a 25-letter sweep over marketing claims, a sterile manufacturing facility caught altering lab records, and a medical device company marketing its products for uses well outside what FDA actually cleared.

Four different enforcement actions. One underlying failure: claims and processes drifting past what was actually validated.

The Headliner: A 25-Letter Sweep Targets Telehealth and Compounded GLP-1 Marketing

The Issue: False and misleading promotional claims, misbranding

On June 16, 2026, FDA's Center for Drug Evaluation and Research (CDER) posted a batch of 25 warning letters issued to telehealth and weight-loss platforms marketing compounded GLP-1 medications (compounded versions of semaglutide and tirzepatide). This follows prior sweeps in late 2025 and March 2026 -- the agency is not slowing down on this category.

The violations across the batch were consistent:

• The "generic" trap. Describing compounded GLP-1s as "generic" versions of Ozempic, Wegovy, or Mounjaro. Compounded medications are not FDA-approved generics, and FDA is enforcing that distinction directly.
• Implying FDA approval. Website language suggesting the specific compounded formulation itself had been approved or evaluated by FDA for safety and efficacy.
• The "clinically proven" illusion. Marketing the compounded drug as "clinically proven" using trial data that was actually generated on the brand-name, FDA-approved counterpart, not the compounded version being sold.
• Masking the compounder. Building a "net impression" that the telehealth provider itself is the manufacturer or compounder, when it is actually a middleman routing prescriptions to a third-party pharmacy.

The Lesson: If you operate in virtual health or compounding, FDA is not just reading your explicit claims. It is evaluating the entire user experience -- logos, taglines, page layout, and the overall "net impression" a patient walks away with. A marketing review process that only checks for banned words will miss this category of violation entirely.

Source Reference: Review the regulatory breakdown of the sweep via the Spakinect National Compliance Registry and Little Health Law Legal Insights.

Manufacturing Failures: Wizcure Pharmaa Private Limited

Warning Letter Reference: 320-26-97

The Issue: Severe CGMP violations, data integrity failures, inadequate sterile processing

FDA issued a stern warning letter to Wizcure Pharmaa following an inspection that uncovered failures in both basic Current Good Manufacturing Practice and sterile manufacturing protocol.

The violations were not clerical gaps -- they were active data manipulation:

• Discarded evidence. Investigators confirmed that original microbial plates showing growth were discarded and replaced with clean plates to cover up unfavorable results.
• Unreliable testing. A systemic failure to reliably incubate environmental monitoring samples and record accurate microbial counts.
• Sterility risks. Flaws in cleanroom design, including the absence of physical barriers separating the ISO 5 filling zone from the surrounding environment, and poor personnel flow in aseptic processing areas.

The Action: FDA strongly recommended the firm retain a qualified CGMP consultant and suspended certain drug production pending a full quality system overhaul.

Source Reference: Read the full official text via the FDA Warning Letter Database (Wizcure Pharmaa Private Limited).

Medical Devices: BlephEx, LLC

Warning Letter Reference: CMS #725861

The Issue: Unapproved device indications, misbranding, and safety omissions

BlephEx, LLC was cited for introducing medical devices into interstate commerce with intended uses well beyond what the devices were legally cleared for.

• The violation. The company marketed products including the BlephEx Powered Eyelid Cleaning Sponge and the OptiVize Ophthalmic Battery-Powered Electrolysis Unit to vulnerable patient populations, including severe dry eye, pre-cataract, and pre-LASIK patients.
• The danger. Marketing claimed the devices could "completely vaporize biofilm lurking within the eyelid" and "blow biofilm off oil-making sacs." FDA noted that extending a device's use to these highly sensitive and inflamed tissue areas introduces unverified safety risks, including corneal abrasions and severe infection risk under surgical flaps.

The Lesson: "Indication creep" -- marketing a product for a use beyond its original 510(k) clearance -- is a fast track to a warning letter. If your marketing materials claim to cure, treat, or structurally alter a condition beyond what your clearance or classification covers, FDA will treat the product as unapproved and misbranded, regardless of how the original device was cleared.

Source Reference: Read the full official text via the FDA Warning Letter Database (BlephEx, LLC).

MedTech Focus: Unauthorized Infection Control and Diagnostics

The Issue: Marketing unauthorized devices and poor complaint processing

Rounding out the month's medtech enforcement, FDA published a string of citations for developers who bypassed the regulatory gateway altogether.

• Device firms were cited for marketing unauthorized sanitation and washing-disinfector devices -- including the UV Smart D25 system -- under incorrect 510(k) exemptions, without the pre-market data validation the technology actually required.
• The citations point to a broader trend: FDA is examining medtech operations where leadership lacks documented training or SOPs for complaint handling and CAPA (Corrective and Preventive Action).

The Lesson: Misapplying an exemption code, or failing to process consumer complaints according to quality system regulations, will trigger an on-site inspection and enforcement action just as reliably as an overt marketing violation.

Source Reference: Tracked via the Regulatory Affairs Professionals Society (RAPS) Enforcement Tracking Report.

Closing Takeaway: Building Guardrails Against Indication Creep and Formulation Gaps

Read together, these four actions point to the same underlying failure, wearing different costumes. Wizcure Pharmaa's discarded microbial plates are a data integrity failure. BlephEx's marketing for uses far outside its cleared indication is a scope failure. The 25-letter telehealth sweep is a marketing-claims failure layered on a compounding process that was never subjected to the same review as an FDA-approved drug. Different mechanisms, same root cause: nothing in the system made it hard to drift past the boundary that was actually approved, tested, or validated.

That is exactly the failure mode a Part 111- and Part 11-native system is built to close.

Locked Master Manufacturing Records (MMRs). Once a formulation is approved in BatchBuddy, the MMR version is locked. Any change requires a change order with two-person approval -- the same control that would have caught a specification, process, or intended-use claim quietly drifting away from what was actually validated, long before it became an unverified marketing claim or an unvalidated sterile process.

Part 11 e-signature gates at every signed action. Every release, approval, and change in BatchBuddy requires a cryptographically verified electronic signature, not a checkbox. If a quality unit or lab technician has to re-authenticate to approve a lot, they cannot quietly swap a failed test result for a clean one and move on -- the kind of substitution investigators found at Wizcure Pharmaa.

Cryptographic, chain-hashed audit trails. Every record in BatchBuddy carries an immutable, hash-chained audit trail entry. If a plate reading, a specification change, or a claims approval is later challenged, the system can prove exactly what was recorded, when, and by whom -- the documentation FDA asks for in a records request, before an inspector ever walks the floor.

None of this stops a company from deciding to market beyond its clearance or cut a corner on sterility testing. What it does is make the paper trail honest enough that those decisions can't hide inside "the system said it was fine." That's the guardrail: not preventing bad judgment, but making sure bad judgment leaves a visible trace before it becomes a Warning Letter.

A Note on This Series

We pull these letters directly from the FDA's public Warning Letter database, which updates continuously. We don't wait for a monthly cycle -- when the FDA posts new letters with patterns worth examining, we cover them.

If you work in supplement, food, or cosmetics manufacturing and want to understand what FDA enforcement trends mean for your operation, this series is written for you.

Read Issue 2 of the Warning Letter Roundup →

See how BatchBuddy's locked MMRs, e-signatures, and audit trail tools work →

Part of our 21 CFR Part 111 Requirements: The Complete Guide hub.